Geode Capital Management LLC Boosts Stake in Sanara MedTech Inc. (NASDAQ:SMTI)

Geode Capital Management LLC raised its holdings in shares of Sanara MedTech Inc. (NASDAQ:SMTI) by 4.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 88,271 shares of the company’s stock after buying an additional 3,755 shares during the period. Geode Capital Management LLC’s holdings in Sanara MedTech were worth $2,670,000 at the end of the most recent reporting period.

Separately, Barclays PLC lifted its stake in shares of Sanara MedTech by 323.0% during the 3rd quarter. Barclays PLC now owns 5,731 shares of the company’s stock worth $174,000 after acquiring an additional 4,376 shares during the last quarter. 8.10% of the stock is currently owned by institutional investors.

Sanara MedTech Trading Down 4.1 %

SMTI stock opened at $32.42 on Wednesday. Sanara MedTech Inc. has a 12 month low of $26.00 and a 12 month high of $41.90. The firm’s 50-day moving average is $34.91 and its 200 day moving average is $32.46. The company has a market capitalization of $283.38 million, a PE ratio of -32.75 and a beta of 1.55. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.23 and a quick ratio of 2.02.

Sanara MedTech (NASDAQ:SMTI) last issued its earnings results on Tuesday, November 12th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.28. The business had revenue of $21.67 million for the quarter. Sanara MedTech had a negative net margin of 10.71% and a negative return on equity of 19.86%. During the same period last year, the business posted ($0.13) earnings per share. On average, research analysts anticipate that Sanara MedTech Inc. will post -1.42 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright started coverage on Sanara MedTech in a report on Monday, December 23rd. They set a “buy” rating and a $50.00 price objective for the company.

Sanara MedTech Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.